{
    "code": "56028961",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=56028961",
    "time": "2018-11-30 03:44:11",
    "許可證字號": "衛部醫器輸字第028961號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "110\/11\/24",
    "發證日期": "105\/11\/24",
    "許可證種類": "醫　器",
    "舊證字號": "",
    "醫療器材級數": "第三等級",
    "通關簽審文件編號": "DHA05602896109",
    "中文品名": "“達克” PD-L1免疫組織化學染色22C3檢測套組",
    "英文品名": "“DAKO” PD-L1 IHC 22C3 pharmDx",
    "效能": "本產品為單株小鼠抗-PD-L1抗體的定性免疫組織化學檢測試劑套組，利用自動免疫組織染色儀(Autostainer Link 48)上的免疫染色分析試劑檢測系統(EnVision FLEX visualization system)，偵測經福馬林固定與石蠟包埋(formalin-fixed,paraffin-embedded;FFPE)處理之非小細胞肺癌(non-small cell lung cancer; NSCLC)組織中的PD-L1蛋白。藉由判讀在任何染色強度下，非壞死腫瘤細胞出現部份或完整細胞膜染色比例的腫瘤比率分數(Tumor Proportion Score;TPS)測定PD-L1蛋白表現量。如果檢體的腫瘤比率分數(TPS) ≥ 1%，則表示有PD-L1蛋白的表現；若腫瘤比率分數(TPS) ≥ 50%，則視為PD-L1蛋白有高表達量。本產品使用在協助找出對KEYTRUDA(pembrolizumab)具感受性治療的NSCLC患者。",
    "醫器規格": "SK006。標籤、仿單變更為：詳如中文仿單核定本（原105年12月8日仿單標籤核定本正本收回作廢）。以下空白。",
    "劑型": "",
    "包裝": "",
    "標籤、仿單及包裝加註": "",
    "": "",
    "醫器主類別一": "B血液學及病理學裝置",
    "醫器次類別一": "B1860免疫病理組織化學試劑與套組",
    "醫器主類別二": "",
    "醫器次類別二": "",
    "醫器主類別三": "",
    "主成分略述": [
        ""
    ],
    "限制項目": "02輸　入",
    "申請商名稱": "6231049608  成信新貿易股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "M464707000  DAKO NORTH AMERICA INC.",
        "製造廠廠址": "1170 Mark Avenue, Carpinteria, CA 93013, USA",
        "製造廠公司地址": "",
        "": ""
    },
    "藥理治療分類": "",
    "ingredients": [],
    "仿單外盒": [
        {
            "title": "560289610001-107.9.6-仿單-107-10-05.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=56028961&Seq=002&Type=9"
        },
        {
            "title": "560289610002-107.9.6-外盒-107-10-05.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=56028961&Seq=002&Type=8"
        }
    ]
}